NEW YORK, NY / ACCESSWIRE / August 17, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Inotiv, Inc. (NASDAQ:NOTV)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/inotiv-shareholder-loss-submission-form?prid=30957&wire=1
Lead Plaintiff Deadline: August 22, 2022
Class Period: September 21, 2021 - June 13, 2022

Allegations against NOTV include that: (1) Inotiv's acquisition, Envigo RMS, LL ('Envigo'), and Inotiv's Cumberland, Virginia facility (the 'Cumberland Facility') engaged in widespread and flagrant violations of the Animal Welfare Act ('AWA'); (2) Envigo and Inotiv's Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Carvana Co. (NYSE:CVNA)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cvna-carvana-loss-submission-form?prid=30957&wire=1
Lead Plaintiff Deadline: October 3, 2022
Class Period: May 6, 2020 - June 24, 2022

Allegations against CVNA include that: (1) Carvana faced serious, ongoing issues with documentation, registration, and title with many of its vehicles; (2) as a result, Carvana was issuing unusually frequent temporary plates; (3) as a result of the foregoing, Carvana was violating laws and regulations in many existing markets; (4) as a result of the foregoing, Carvana risked its ability to continue business and/or expand its business in existing markets; (5) as a result of the foregoing, Carvana was at an increased risk of governmental investigation and action; (6) Carvana was in discussion with state and local authorities regarding the above-stated business tactics and issues; (7) Carvana was facing imminent and ongoing regulatory actions including license suspensions, business cessation, and probation in several states and counties including in Arizona, Illinois, Pennsylvania, Michigan, and North Carolina; and (8) as a result, Defendants' statements about Carvana's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Kiromic BioPharma, Inc. (NASDAQ:KRBP)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kiromic-biopharma-inc-loss-submission-form?prid=30957&wire=1
Lead Plaintiff Deadline: October 4, 2022
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.

The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE: The Law Offices of Vincent Wong